File Download
There are no files associated with this item.
Supplementary
-
Citations:
- Appears in Collections:
Conference Paper: Efficacy and safety of ticagrelor versus clopidogrel in patients with stable coronary artery diseases: a systematic review and meta-analysis
Title | Efficacy and safety of ticagrelor versus clopidogrel in patients with stable coronary artery diseases: a systematic review and meta-analysis |
---|---|
Authors | |
Issue Date | 2020 |
Publisher | Hong Kong Academy of Medicine Press. The Journal's web site is located at http://www.hkmj.org/ |
Citation | The 25th Annual Medical Research Conference, Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, 18 January 2020. In Hong Kong Medical Journal, 2020, v. 26 n. 1, Suppl. 1, p. 34, abstract no. 55 How to Cite? |
Abstract | Objective: Ticagrelor has been recommended for acute coronary syndrome with percutaneous coronary
intervention, but its efficacy and safety comparative to clopidogrel in patients with stable coronary artery
disease remains inconsistent.
Methods: This was a systematic review and meta-analysis. Embase and Medline was searched through
November 2019. Studies were eligible when they compared ticagrelor and clopidogrel in patients with stable coronary artery disease regarding the outcomes of interest. Patient characteristics, treatment regimens, and outcome data were extracted. The primary outcome was major adverse cardiac events (MACE), and the secondary outcomes included major bleeding, cardiovascular death, and non-fatal myocardial infarction (MI). Random-effects model was used to combine the results across studies. Sensitivity analysis by including only randomised trials was conducted.
Results: Out of 231 citations, three studies (2 randomised trials and 1 cohort study) with 8827 patients (4353 on ticagrelor and 4474 on clopidogrel) were eligible. The median follow-up time ranged from 17 months to 24 months. Overall, compared with clopidogrel, ticagrelor did not show significant difference in reducing the risks of MACE (relative risk [RR]=0.87, 95% confidence interval [CI]=0.72-1.07), non-fatal MI (RR=0.67, 95% CI=0.24-1.88), cardiovascular death (RR=1.51, 95% CI=0.35-6.51), and major bleeding (RR=1.32, 95% CI=0.97-1.79). Similar results were also observed in sensitivity analysis.
Conclusion: This study did not provide evidence that ticagrelor was more effective or safer than clopidogrel in patients with stable coronary artery disease. However, the small number of included studies should be borne in mind when interpreting the results. |
Persistent Identifier | http://hdl.handle.net/10722/281732 |
ISSN | 2023 Impact Factor: 3.1 2023 SCImago Journal Rankings: 0.261 |
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Feng, Q | - |
dc.contributor.author | Fei, Y | - |
dc.contributor.author | Tsoi, MF | - |
dc.contributor.author | Cheung, BMY | - |
dc.date.accessioned | 2020-03-22T04:18:52Z | - |
dc.date.available | 2020-03-22T04:18:52Z | - |
dc.date.issued | 2020 | - |
dc.identifier.citation | The 25th Annual Medical Research Conference, Department of Medicine, The University of Hong Kong, Queen Mary Hospital, Hong Kong, 18 January 2020. In Hong Kong Medical Journal, 2020, v. 26 n. 1, Suppl. 1, p. 34, abstract no. 55 | - |
dc.identifier.issn | 1024-2708 | - |
dc.identifier.uri | http://hdl.handle.net/10722/281732 | - |
dc.description.abstract | Objective: Ticagrelor has been recommended for acute coronary syndrome with percutaneous coronary intervention, but its efficacy and safety comparative to clopidogrel in patients with stable coronary artery disease remains inconsistent. Methods: This was a systematic review and meta-analysis. Embase and Medline was searched through November 2019. Studies were eligible when they compared ticagrelor and clopidogrel in patients with stable coronary artery disease regarding the outcomes of interest. Patient characteristics, treatment regimens, and outcome data were extracted. The primary outcome was major adverse cardiac events (MACE), and the secondary outcomes included major bleeding, cardiovascular death, and non-fatal myocardial infarction (MI). Random-effects model was used to combine the results across studies. Sensitivity analysis by including only randomised trials was conducted. Results: Out of 231 citations, three studies (2 randomised trials and 1 cohort study) with 8827 patients (4353 on ticagrelor and 4474 on clopidogrel) were eligible. The median follow-up time ranged from 17 months to 24 months. Overall, compared with clopidogrel, ticagrelor did not show significant difference in reducing the risks of MACE (relative risk [RR]=0.87, 95% confidence interval [CI]=0.72-1.07), non-fatal MI (RR=0.67, 95% CI=0.24-1.88), cardiovascular death (RR=1.51, 95% CI=0.35-6.51), and major bleeding (RR=1.32, 95% CI=0.97-1.79). Similar results were also observed in sensitivity analysis. Conclusion: This study did not provide evidence that ticagrelor was more effective or safer than clopidogrel in patients with stable coronary artery disease. However, the small number of included studies should be borne in mind when interpreting the results. | - |
dc.language | eng | - |
dc.publisher | Hong Kong Academy of Medicine Press. The Journal's web site is located at http://www.hkmj.org/ | - |
dc.relation.ispartof | Hong Kong Medical Journal | - |
dc.relation.ispartof | 25th Medical Research Conference | - |
dc.rights | Hong Kong Medical Journal. Copyright © Hong Kong Academy of Medicine Press. | - |
dc.title | Efficacy and safety of ticagrelor versus clopidogrel in patients with stable coronary artery diseases: a systematic review and meta-analysis | - |
dc.type | Conference_Paper | - |
dc.identifier.email | Feng, Q: qifeng@hku.hk | - |
dc.identifier.email | Tsoi, MF: smftsoi@hku.hk | - |
dc.identifier.email | Cheung, BMY: mycheung@hkucc.hku.hk | - |
dc.identifier.authority | Cheung, BMY=rp01321 | - |
dc.identifier.hkuros | 309420 | - |
dc.identifier.volume | 26 | - |
dc.identifier.issue | 1, Suppl. 1 | - |
dc.identifier.spage | 34, abstract no. 55 | - |
dc.identifier.epage | 34, abstract no. 55 | - |
dc.publisher.place | Hong Kong | - |
dc.identifier.issnl | 1024-2708 | - |